ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,495.20
0.00%
S&P ASX All Technology
4,017.00
0.00%
Brent Oil
73.465
2.19%
US Dollar vs AUD
1.54253
-0.13%
Bitcoin
95,967.96
0.11%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. IO Biotech Inc (IOBT) Share Price

IO Biotech Inc

IO Biotech Inc (IOBT)

NASDAQ
0.8604
-0.0385
(-4.28%)
At close: 04 December 8:00AM
Delayed by 15 minutes
0.8329
-0.0275
( -3.20% )
After Hours: 8:02AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.8329
Bid
0.8329
Offer
0.90
Volume
406,035
0.8104 Day's Range 0.935108
0.66 52 Week Range 2.098
Market Cap
54.872M
Previous Close
0.8989
Open
0.935108
Last Trade
980
@
0.8329
(formt)
Last Trade Time
08:02:09
Financial Volume
US$ 348,348
VWAP
0.857925
Average Volume (3m)
565,702
Shares Outstanding
65,880,914
Dividend Yield
-
PE Ratio
-0.64
Earnings Per Share (EPS)
-1.31
Revenue
-
Net Profit
-86.08M

About IO Biotech Inc

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.iobiotech.com
Headquarters
Wilmington, Delaware, USA
Founded
-
IO Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IOBT. The last closing price for IO Biotech was US$0.90. Over the last year, IO Biotech shares have traded in a share price range of US$ 0.66 to US$ 2.098.

IO Biotech currently has 65,880,914 shares in issue. The market capitalisation of IO Biotech is US$59.22 million. IO Biotech has a price to earnings ratio (PE ratio) of -0.64.

Ask ADVFN Intelligence (AI)

IOBT Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

13 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

12 November 2024
Edgar (US Regulatory)

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with...

12 November 2024
GlobeNewswire Inc.

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...

12 November 2024
GlobeNewswire Inc.

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response...

08 November 2024
GlobeNewswire Inc.

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...

04 October 2024
GlobeNewswire Inc.

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety...

14 September 2024
GlobeNewswire Inc.

Form 8-K - Current report

31 August 2024
Edgar (US Regulatory)

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety...

31 August 2024
GlobeNewswire Inc.

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

27 August 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.07299.592105263160.760.950.714307680.84523206CS
4-0.3172-27.58021041651.15011.290.667600370.84048888CS
12-0.077101-8.472628052060.9100011.420.665657020.94323702CS
26-0.3671-30.59166666671.21.730.663668721.0406879CS
52-0.3871-31.72950819671.222.0980.662462471.17998077CS
156-9.0071-91.53556910579.8412.580.661435612.12894698CS
260-15.1671-94.7943751617.880.661438522.40732714CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HTOOFusion Fuel Green PLC
US$ 0.5532
(75.06%)
3.66M
OKTAOkta Inc
US$ 97.5001
(19.19%)
1.51M
VIRXViracta Therapeutics Inc
US$ 0.1869
(14.80%)
822.45k
SMSISmith Micro Software Inc
US$ 0.8799
(11.22%)
3.28k
LIFWMSP Recovery Inc
US$ 1.78
(9.20%)
103.76k
ORISOriental Rise Holdings Ltd
US$ 7.4755
(-32.71%)
274.82k
BASECouchbase Inc
US$ 18.07
(-14.48%)
24.2k
CTNTCheetah Net Supply Chain Service Inc
US$ 4.25
(-11.64%)
286.74k
ALTSALT5 Sigma Corporation
US$ 2.58
(-9.47%)
2k
NAASNaaS Technology Inc
US$ 2.69
(-8.81%)
41.39k
NVDANVIDIA Corporation
US$ 140.26
(0.01%)
4.85M
HTOOFusion Fuel Green PLC
US$ 0.5532
(75.06%)
3.66M
BILIBilibili Inc
US$ 19.22
(0.05%)
2.48M
OKTAOkta Inc
US$ 97.5001
(19.19%)
1.51M
MRVLMarvell Technology Inc
US$ 95.91
(-0.09%)
1.17M

IOBT Discussion

View Posts
ZLAZARUS ZLAZARUS 1 week ago
Ph3 melanoma data for IO102-IO103 remain on track for 1H25 and represents the next key catalyst. At .70 we are trading at cash. With a positive Ph3 melanoma readout we will be trading at $3.00 overnight with a march to $6.00 towards the later half of 2025. In addition, I'm encouraged by the supportive data in additional solid tumors which increases my confidence in the potential for success in the ongoing Ph3 melanoma study.

Also lets remember the IO102-IO103 melanoma study is with Merck's + pembrolizumab Ketruda. If IOBT's IO102-IO103 is approved, it will be a disruptive game changer thus creating an overnight valuation of about 200 million for the company in 2025. Leading into 2026, we could see a valuation conservatively of about $400M. This is my opinion.
👍️0
ZLAZARUS ZLAZARUS 2 weeks ago
Picked up at 20,000 shares @ .88 , I will pick up more when it drops below .73
👍️0
phrocks phrocks 2 weeks ago
Now you're a participant??
👍️0
ZLAZARUS ZLAZARUS 2 weeks ago
Targeting a fill between .70 & .78 Gem here on positive IOB-013/KN-D18 Q1 2025 Phase III results.
👍️0
Rkrocks Rkrocks 2 months ago
No real volume
👍️0
Rkrocks Rkrocks 2 months ago
Monk are we finally on the move with this?
👍️0
axelvento axelvento 2 months ago
O Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and IDO, and which has breakthrough therapy designation. A pivotal study in first line metastatic melanoma will read out soon.

https://www.biotechtv.com/post/io-biotech-october-11-2024
👍️0
Monksdream Monksdream 2 months ago
IOBT under $2


👍️0
glenn1919 glenn1919 2 months ago
IOBT.................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783
👍️0
axelvento axelvento 2 months ago
IOBiotech
is pleased to announce that it will be presenting two posters at the SITC 2024 Annual Meeting.

The first poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in our Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The second poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.

We look forward to sharing these exciting data at the meeting which takes place in Houston from November 6-10, 2024. See full details here:

https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Two-Poster-Presentations-at-the-Society-for-Immunotherapy-of-Cancers-SITC-39th-Annual-Meeting/default.aspx
👍️0
glenn1919 glenn1919 3 months ago
iobt................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 months ago
IOBT new 52 week low
https://investorshub.advfn.com/uimage/uploads/2024/9/12/fmdniIMG_1694.gif
👍️0
Monksdream Monksdream 3 months ago
IOBT under $2
👍️0
PonkenPlonken PonkenPlonken 4 months ago
starting to run into the readout
Lead investigator and advisors that helped BMS in making ipi+nivo the new SOC --- They now work on this. Cancer vaccines back in fashion.
👍️0
PonkenPlonken PonkenPlonken 4 months ago
Sorry for the late reply, im not yet fully familiar with this platform.
The SOC for advanced melanoma is Ipi + Nivo which is neither very helpful nor very safe. Hence "the bar is hanging low" here.
👍️0
Monksdream Monksdream 4 months ago
IOBT
👍️0
stock1ace1 stock1ace1 5 months ago
Standard of care …
👍️0
Monksdream Monksdream 5 months ago
IOBT under $2
👍️0
ralfito ralfito 6 months ago
For us dummies, can you define SOC in this context? Thanks.
👍️0
PonkenPlonken PonkenPlonken 6 months ago
CEO made it pretty clear numerous times at Jefferies IMO
they will become the SOC, not only in advanced melanoma but in all stages.
They also think their platform can be used for non-cancer indications.

2 Birds in the hand and many more in the bush$$$
👍️0
PonkenPlonken PonkenPlonken 6 months ago
https://www.youtu be.com/watch?v=OvC-86SN9Ao&ab_channel=VJOncology

australian KOL on IOBT

many things pointing at it becoming the SOC one day...
👍️0
axelvento axelvento 6 months ago
golden cross MA50 MA200
👍️0
axelvento axelvento 7 months ago
a planned interim analysis of ORR will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024 and, if supportive, we believe could allow for submission of a BLA for accelerated approval in the US.
Cash and cash equivalents as of March 31, 2024 were $118.0 million, compared to $143.2 million at December 31, 2023. During the three months ended March 31, 2024, the company used cash, cash equivalents and restricted cash of $24.9 million. The increase in cash use was primarily driven by milestone payments and payment of other accrued expenses associated with clinical trials, as well as the payment of year-end bonuses. The company continues to expect that it will have sufficient cash to run the company into the fourth quarter of 2025.
👍️0
axelvento axelvento 7 months ago
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors
Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025

https://www.biopharmcatalyst.com/company/IOBT/news/190095
👍️0
axelvento axelvento 7 months ago
https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Abstract-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspx
👍️0
axelvento axelvento 8 months ago
IO Biotech was founded in 2014 and just 10 years into the journey we are in a pivotal phase III trial I think that’s quite fast
👍️0
axelvento axelvento 8 months ago
next catalyst-In November 2023, the company completed enrollment of 380 patients in its pivotal Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in advanced melanoma. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the second half of 2025. Additionally, a planned interim analysis of overall response rate (ORR) will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024.
👍️0
Monksdream Monksdream 9 months ago
IOBT under $2
👍️0
Monksdream Monksdream 9 months ago
IOBT under $2
👍️0
Monksdream Monksdream 1 year ago
IOBT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
IOBT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
IOBT ubder $2
👍️0
AJ Freely AJ Freely 1 year ago
$IOBT - 👆Up 1.8% Pre-Market/ Current Price $2.00
Announces $75 Million Private Placement Financing
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
kzivann kzivann 1 year ago
Extremely heavy volume on good news. PPS down . Lower this AM. Watching

IOBT
👍️0
Phosphene Phosphene 3 years ago
IO Biotech’s (NASDAQ:IOBT ) lock-up period is set to end on Wednesday, May 4th.

https://www.defenseworld.net/2022/04/27/io-biotech-inc-s-lock-up-period-set-to-end-on-may-4th-nasdaqiobt.html
👍️0
conix conix 3 years ago
Bitoechs are waking up ---like they did last year.

I shopped for a number of sold out biotechs in December and picked and chose a number of sold out biotechs.

IOBT --I missed. But there are legs here. I have done well on four of my picks. Still waiting on two.

Time will tell.
👍️0
Phosphene Phosphene 3 years ago
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

https://www.globenewswire.com/news-release/2021/12/06/2346557/0/en/IO-Biotech-Announces-Third-Clinical-Collaboration-with-Merck-to-Evaluate-IO102-IO103-in-Combination-With-KEYTRUDA-pembrolizumab-as-First-Line-Treatment-in-a-Phase-2-Multi-Arm-Baske.html

👍️0
Eggplant Eggplant 3 years ago
What happened? IPO at $14/sh four weeks ago, and the stock has nearly folded in half. No news, and the only sellers should be the IPO buyers, right? Mystery.
👍️0
Work Harder Work Harder 3 years ago
I was right on the 7

for now

Yu tell wifeie

I appreciate her time

:}
👍️0
Phosphene Phosphene 3 years ago
Did Sunstone/Verland recoup initial seed?









👍️0
Staypositive1 Staypositive1 3 years ago
might wait till .035...lol
👍️0
Phosphene Phosphene 3 years ago
IO Biotech begins trading on Nasdaq Global Market today.

IPO pps is $14.

Thu, November 4, 2021, 11:52 PM.

https://finance.yahoo.com/news/io-biotech-inc-announces-pricing-035200314.html?fr=sycsrp_catchall

Sunstone and Novo Holdings involved.
👍️0
Phosphene Phosphene 3 years ago
EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL

https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/


IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html
👍️0
Phosphene Phosphene 3 years ago
Denmark's IO Biotech seeks $110M+ in Nasdaq debut.

https://pitchbook.com/newsletter/denmarks-io-biotech-seeks-110m-in-nasdaq-debut

https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

https://www.iobiotech.com/

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma

https://www.firstwordpharma.com/node/1783725?tsid=17
👍️0

Your Recent History

NASDAQ
IOBT
IO Biotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved